Type Size

    Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomized trial.

    The authors found that combined treatment with teriparatide and denosumab increased BMD more than either agent alone and more than has been reported with approved therapies. Therefore, they conclude that combination treatment might be useful for patients at high risk of fracture.

    Read Article